[Skip to Content]
[Skip to Content Landing]
August 22, 1986

The Management of Hyperlipoproteinemia

Author Affiliations

Gundersen Clinic La Crosse, Wis

Gundersen Clinic La Crosse, Wis

JAMA. 1986;256(8):1003. doi:10.1001/jama.1986.03380080049024

To the Editor.—  The proposition from the National Institutes of Health Consensus Development Conference1 that one of every ten American adults should be given drug therapy to lower blood cholesterol levels is staggering and warrants further comment. In their "An Approach to the Management of Hyperlipoproteinemia,"2 Hoeg et al also recommended drug treatment for persons in the top tenth percentile and referred to the Coronary Drug Project as supporting the use of niacin. Challenged that no prospective drug trial has yet shown lower coronary mortality in the treatment group3— including the Coronary Drug Project— these advocates cited a follow-up study by Canner that might suggest a late beneficial effect of niacin.4